Telomir Pharmaceuticals, Inc. has completed an IPO in the amount of $7 million.

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. TELOMIR-1 serve as a metal enzyme inhibitor of essential metals such as zinc and copper. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The Company’s BioMAP platform provides an unbiased, target-agnostic, and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers.